GlaxoSmithKline, Harvard Stem Cell Institute, Cenix BioSciences, Regulus Therapeutics, National Institutes of Health, BioFocus DPI, Wellcome Trust, European Molecular Biology Laboratory, European Bioinformatics Institute, Beckman Coulter, PerkinElmer | GenomeWeb
GSK, HSCI Ink $25M Collaboration Deal; Will Develop Cardiomyocyte Models for Screening 
GlaxoSmithKline and the Harvard Stem Cell Institute this week announced that they have entered into a five-year, $25 million-plus collaborative agreement to expedite the development of treatments and cures for a range of diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.